{"id":136782,"date":"2025-05-13T14:04:31","date_gmt":"2025-05-13T18:04:31","guid":{"rendered":"https:\/\/medcitynews.com\/?p=136782"},"modified":"2025-05-14T23:08:52","modified_gmt":"2025-05-15T03:08:52","slug":"galapagos-strategic-alternatives-spinco-cell-therapy-cancer-glpg","status":"publish","type":"post","link":"https:\/\/medcitynews.com\/2025\/05\/galapagos-strategic-alternatives-spinco-cell-therapy-cancer-glpg\/","title":{"rendered":"Galapagos Says \u2018No\u2019 to SpinCo and Instead Will Seek Deals for All Assets"},"content":{"rendered":"

Galapagos believed so strongly in its work developing new cancer cell therapies that it pinned its future on them. This past winter, the Belgian drugmaker unveiled a plan to spin out the rest of the company as a standalone business<\/a>, leaving legacy Galapagos to focus exclusively on its new approach to manufacturing and supplying CAR T-cell therapies. Now it\u2019s halting the spinoff plans and is instead exploring strategic alternatives for everything \u2014 including cell therapy.<\/p>\n

The re-evaluation of the planned business separation follows unspecified \u201cregulatory and market developments,\u201d Galapagos said Tuesday<\/a>. The company is not winding down. But by exploring business deals for its existing business assets, the Galapagos board of directors aims to maximize the financial resources the company can deploy toward \u201ctransformative business development transactions.\u201d<\/p>\n

Galapagos, founded in 1999, initially focused on developing small molecule drugs for inflammatory disorders. The company changed course in recent years with deals that gave it access to cell therapy technologies. These technologies enabled the company to do cell therapy manufacturing at or near the point of care<\/a>, a decentralized approach that stands in contrast to current manufacturing practices in which a patient\u2019s cells are engineered and expanded in a distant lab, a multi-step process that can take a month or more.<\/p>\n

The most advanced Galapagos cell therapy program is GLPG5101. Though Galapagos generated encouraging early clinical data for this therapy in non-Hodgkin lymphoma<\/a>, the company later selected mantle cell lymphoma (MCL) as the lead indication; a potentially pivotal clinical study was planned to start in 2026.<\/p>\n

MCL is a competitive indication that earlier this year welcomed AstraZeneca BTK inhibitor Calquence as a new first-line treatment for this rare blood cancer<\/a>. Eli Lilly\u2019s Jaypirca, also a BTK inhibitor, has accelerated FDA approval<\/a> as a third-line MCL treatment. As for cell therapies, the FDA\u2019s 2020 approval of Tecartus made that Gilead Sciences cell therapy the first CAR T-treatment for MCL<\/a>. Nearly a year ago, Bristol Myers Squibb\u2019s Breyanzi expanded its label to include third-line treatment of MCL.<\/p>\n

SpinCo was not envisioned as a way to develop and commercialize the non-cell therapy pieces of the Galapagos pipeline. When the spinoff plan was announced, Galapagos said it would seek partners or deals for its clinical-stage immunology drug as well as its preclinical assets. SpinCo would combine cash from those transactions with \u20ac2.45 billion (about $2.5 billion) in capital from Galapagos to acquire or license clinical-stage drugs in oncology, immunology, and virology.<\/p>\n

Weeks ago, the spinoff appeared to be proceeding as planned. Galapagos announced its CEO, Paul Stoffels, would retire<\/a> upon the appointment of a successor in the next year and biopharma industry veteran Henry Gosebruch was named the new CEO of the SpinCo. In its report of first quarter 2025 financial results<\/a>, the company said the spinoff was still on track to happen in mid-2025.<\/p>\n

Galapagos said Tuesday that its board of directors has appointed Gosebruch to serve as CEO of the company effective immediately, succeeding Stoffels, who has retired. Gosebruch now takes on the responsibility for pursuing strategic alternatives for Galapagos\u2019s assets and for striking deals to build a new drug pipeline. As of the end of the first quarter of this year, Galapagos reported its cash position was \u20ac3.3 billion (about $3.7 billion).<\/p>\n

To Leerink Partners analyst Faisal Khurshid, Galapagos\u2019s change in course is a recognition that its CAR T-platform alone was unlikely to sustain an independent company. Leerink had a cautious view of the cell therapy platform, given the logistical challenges and limited evidence of clinical differentiation from already available cell therapies.<\/p>\n

\u201cWhile we await additional details on next steps we think this may enable [Galapagos] to pursue further [business development] and build out an innovative pipeline which may be of interest to investors,\u201d Khurshid wrote in a note sent to investors. \u201cWe see this move as tacit acknowledgement that an independent company focused on this platform would not be sustainable from an investor interest and financing capability perspective.\u201d<\/p>\n

Photo: Yuriko Nakao, Getty Images<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Galapagos has dropped plans for a business separation that would have enabled the legacy company to focus exclusively on developing new cancer cell therapies. Instead, Galapagos said it will pursue strategic alternatives for its assets.<\/p>\n","protected":false},"author":25932,"featured_media":10404,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"featured_image_focal_point":[],"homepage_placement":"top","homepage_placements":{"top":true,"featured":true,"sidebar":false},"homepage_alternative_layout":false,"featured_categories":[54,69],"hide_from_feed":false,"footnotes":""},"categories":[69,63,54],"tags":[42355,14217,37220,29460,12102,46027,11205,42347],"class_list":["post-136782","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biopharma","category-daily","category-pharma-channel","tag-biopharma-nl","tag-cancer","tag-car-t","tag-cell-therapy","tag-clinical-trials","tag-deals","tag-galapagos","tag-mantle-cell-lymphoma"],"acf":[],"yoast_head":"\nGalapagos Says \u2018No\u2019 to SpinCo and Instead Will Seek Deals for All Assets - MedCity News<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/medcitynews.com\/2025\/05\/galapagos-strategic-alternatives-spinco-cell-therapy-cancer-glpg\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Galapagos Says \u2018No\u2019 to SpinCo and Instead Will Seek Deals for All Assets - MedCity News\" \/>\n<meta property=\"og:description\" content=\"Galapagos has dropped plans for a business separation that would have enabled the legacy company to focus exclusively on developing new cancer cell therapies. Instead, Galapagos said it will pursue strategic alternatives for its assets.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/medcitynews.com\/2025\/05\/galapagos-strategic-alternatives-spinco-cell-therapy-cancer-glpg\/\" \/>\n<meta property=\"og:site_name\" content=\"MedCity News\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-13T18:04:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-15T03:08:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/12\/GettyImages-1248814131.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"683\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Frank Vinluan\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@frankvinluan\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Frank Vinluan\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/medcitynews.com\/2025\/05\/galapagos-strategic-alternatives-spinco-cell-therapy-cancer-glpg\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/medcitynews.com\/2025\/05\/galapagos-strategic-alternatives-spinco-cell-therapy-cancer-glpg\/\"},\"author\":{\"name\":\"Frank Vinluan\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\"},\"headline\":\"Galapagos Says \u2018No\u2019 to SpinCo and Instead Will Seek Deals for All Assets\",\"datePublished\":\"2025-05-13T18:04:31+00:00\",\"dateModified\":\"2025-05-15T03:08:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/medcitynews.com\/2025\/05\/galapagos-strategic-alternatives-spinco-cell-therapy-cancer-glpg\/\"},\"wordCount\":672,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/medcitynews.com\/2025\/05\/galapagos-strategic-alternatives-spinco-cell-therapy-cancer-glpg\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/12\/GettyImages-1248814131.jpg\",\"keywords\":[\"biopharma nl\",\"cancer\",\"CAR-T\",\"cell therapy\",\"Clinical Trials\",\"Deals\",\"Galapagos\",\"mantle cell lymphoma\"],\"articleSection\":[\"BioPharma\",\"Daily\",\"Pharma\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/medcitynews.com\/2025\/05\/galapagos-strategic-alternatives-spinco-cell-therapy-cancer-glpg\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/medcitynews.com\/2025\/05\/galapagos-strategic-alternatives-spinco-cell-therapy-cancer-glpg\/\",\"url\":\"https:\/\/medcitynews.com\/2025\/05\/galapagos-strategic-alternatives-spinco-cell-therapy-cancer-glpg\/\",\"name\":\"Galapagos Says \u2018No\u2019 to SpinCo and Instead Will Seek Deals for All Assets - MedCity News\",\"isPartOf\":{\"@id\":\"https:\/\/medcitynews.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/medcitynews.com\/2025\/05\/galapagos-strategic-alternatives-spinco-cell-therapy-cancer-glpg\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/medcitynews.com\/2025\/05\/galapagos-strategic-alternatives-spinco-cell-therapy-cancer-glpg\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/12\/GettyImages-1248814131.jpg\",\"datePublished\":\"2025-05-13T18:04:31+00:00\",\"dateModified\":\"2025-05-15T03:08:52+00:00\",\"author\":{\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\"},\"breadcrumb\":{\"@id\":\"https:\/\/medcitynews.com\/2025\/05\/galapagos-strategic-alternatives-spinco-cell-therapy-cancer-glpg\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/medcitynews.com\/2025\/05\/galapagos-strategic-alternatives-spinco-cell-therapy-cancer-glpg\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/medcitynews.com\/2025\/05\/galapagos-strategic-alternatives-spinco-cell-therapy-cancer-glpg\/#primaryimage\",\"url\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/12\/GettyImages-1248814131.jpg\",\"contentUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/12\/GettyImages-1248814131.jpg\",\"width\":1024,\"height\":683,\"caption\":\"Galapagos\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/medcitynews.com\/2025\/05\/galapagos-strategic-alternatives-spinco-cell-therapy-cancer-glpg\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/medcitynews.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Galapagos Says \u2018No\u2019 to SpinCo and Instead Will Seek Deals for All Assets\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/medcitynews.com\/#website\",\"url\":\"https:\/\/medcitynews.com\/\",\"name\":\"MedCity News\",\"description\":\"Healthcare technology news, life science current events\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/medcitynews.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\",\"name\":\"Frank Vinluan\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg\",\"contentUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg\",\"caption\":\"Frank Vinluan\"},\"description\":\"Frank Vinluan is senior biopharma reporter for MedCity News. He previously held business reporting positions at Xconomy, The Seattle Times, The Des Moines Register, and the Triangle Business Journal. LinkedIn: https:\/\/www.linkedin.com\/in\/frankvinluan\/ Twitter: @frankvinluan\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/frankvinluan\/\",\"https:\/\/x.com\/frankvinluan\"],\"url\":\"https:\/\/medcitynews.com\/author\/fvinluan\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Galapagos Says \u2018No\u2019 to SpinCo and Instead Will Seek Deals for All Assets - MedCity News","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/medcitynews.com\/2025\/05\/galapagos-strategic-alternatives-spinco-cell-therapy-cancer-glpg\/","og_locale":"en_US","og_type":"article","og_title":"Galapagos Says \u2018No\u2019 to SpinCo and Instead Will Seek Deals for All Assets - MedCity News","og_description":"Galapagos has dropped plans for a business separation that would have enabled the legacy company to focus exclusively on developing new cancer cell therapies. Instead, Galapagos said it will pursue strategic alternatives for its assets.","og_url":"https:\/\/medcitynews.com\/2025\/05\/galapagos-strategic-alternatives-spinco-cell-therapy-cancer-glpg\/","og_site_name":"MedCity News","article_published_time":"2025-05-13T18:04:31+00:00","article_modified_time":"2025-05-15T03:08:52+00:00","og_image":[{"width":1024,"height":683,"url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/12\/GettyImages-1248814131.jpg","type":"image\/jpeg"}],"author":"Frank Vinluan","twitter_card":"summary_large_image","twitter_creator":"@frankvinluan","twitter_misc":{"Written by":"Frank Vinluan","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/medcitynews.com\/2025\/05\/galapagos-strategic-alternatives-spinco-cell-therapy-cancer-glpg\/#article","isPartOf":{"@id":"https:\/\/medcitynews.com\/2025\/05\/galapagos-strategic-alternatives-spinco-cell-therapy-cancer-glpg\/"},"author":{"name":"Frank Vinluan","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35"},"headline":"Galapagos Says \u2018No\u2019 to SpinCo and Instead Will Seek Deals for All Assets","datePublished":"2025-05-13T18:04:31+00:00","dateModified":"2025-05-15T03:08:52+00:00","mainEntityOfPage":{"@id":"https:\/\/medcitynews.com\/2025\/05\/galapagos-strategic-alternatives-spinco-cell-therapy-cancer-glpg\/"},"wordCount":672,"commentCount":0,"image":{"@id":"https:\/\/medcitynews.com\/2025\/05\/galapagos-strategic-alternatives-spinco-cell-therapy-cancer-glpg\/#primaryimage"},"thumbnailUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/12\/GettyImages-1248814131.jpg","keywords":["biopharma nl","cancer","CAR-T","cell therapy","Clinical Trials","Deals","Galapagos","mantle cell lymphoma"],"articleSection":["BioPharma","Daily","Pharma"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/medcitynews.com\/2025\/05\/galapagos-strategic-alternatives-spinco-cell-therapy-cancer-glpg\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/medcitynews.com\/2025\/05\/galapagos-strategic-alternatives-spinco-cell-therapy-cancer-glpg\/","url":"https:\/\/medcitynews.com\/2025\/05\/galapagos-strategic-alternatives-spinco-cell-therapy-cancer-glpg\/","name":"Galapagos Says \u2018No\u2019 to SpinCo and Instead Will Seek Deals for All Assets - MedCity News","isPartOf":{"@id":"https:\/\/medcitynews.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/medcitynews.com\/2025\/05\/galapagos-strategic-alternatives-spinco-cell-therapy-cancer-glpg\/#primaryimage"},"image":{"@id":"https:\/\/medcitynews.com\/2025\/05\/galapagos-strategic-alternatives-spinco-cell-therapy-cancer-glpg\/#primaryimage"},"thumbnailUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/12\/GettyImages-1248814131.jpg","datePublished":"2025-05-13T18:04:31+00:00","dateModified":"2025-05-15T03:08:52+00:00","author":{"@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35"},"breadcrumb":{"@id":"https:\/\/medcitynews.com\/2025\/05\/galapagos-strategic-alternatives-spinco-cell-therapy-cancer-glpg\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/medcitynews.com\/2025\/05\/galapagos-strategic-alternatives-spinco-cell-therapy-cancer-glpg\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medcitynews.com\/2025\/05\/galapagos-strategic-alternatives-spinco-cell-therapy-cancer-glpg\/#primaryimage","url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/12\/GettyImages-1248814131.jpg","contentUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/12\/GettyImages-1248814131.jpg","width":1024,"height":683,"caption":"Galapagos"},{"@type":"BreadcrumbList","@id":"https:\/\/medcitynews.com\/2025\/05\/galapagos-strategic-alternatives-spinco-cell-therapy-cancer-glpg\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/medcitynews.com\/"},{"@type":"ListItem","position":2,"name":"Galapagos Says \u2018No\u2019 to SpinCo and Instead Will Seek Deals for All Assets"}]},{"@type":"WebSite","@id":"https:\/\/medcitynews.com\/#website","url":"https:\/\/medcitynews.com\/","name":"MedCity News","description":"Healthcare technology news, life science current events","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/medcitynews.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35","name":"Frank Vinluan","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/image\/","url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg","contentUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg","caption":"Frank Vinluan"},"description":"Frank Vinluan is senior biopharma reporter for MedCity News. He previously held business reporting positions at Xconomy, The Seattle Times, The Des Moines Register, and the Triangle Business Journal. LinkedIn: https:\/\/www.linkedin.com\/in\/frankvinluan\/ Twitter: @frankvinluan","sameAs":["https:\/\/www.linkedin.com\/in\/frankvinluan\/","https:\/\/x.com\/frankvinluan"],"url":"https:\/\/medcitynews.com\/author\/fvinluan\/"}]}},"_links":{"self":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts\/136782","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/users\/25932"}],"replies":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/comments?post=136782"}],"version-history":[{"count":0,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts\/136782\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/media\/10404"}],"wp:attachment":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/media?parent=136782"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/categories?post=136782"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/tags?post=136782"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}